soul trial oral semaglutide cardiovascular outcomes 2025 Best of EASD by the EASD Early Career Academy – featuring Dr. Michael Leutner soul trial semaglutide (NEJM 2025):

Her background includes a senior role at a leading laser aesthetics group, giving her deep insight into safe and effective treatment delivery across diverse skin types

Glucose and lipid pathway analysis: Exploration of multi-pathway metabolic responses

The World Health Organization (WHO) released guidelines in December 2025 summarizing its recommendations for the use of GLP-1s to treat obesity

Kamada K, Goto S, Okunaga T, Ihara Y, Tsuji K, Kawai Y et al

Targeted protein degradation directly engaging lysosomes or proteasomes

This formula combines clinical expertise with deep understanding of digestive challenges faced by GLP-1 users and those with sensitive stomachs